Quicksilver Scientific

Due to inclement weather and increased order volume expect shipping delays. 

Free shipping over $50

0

Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

NAD+ Gold References

  1. Longo VD et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 14 (4): 497-510. View Abstract
  2. Fang EF et al. NAD (+) in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899–916 View Abstract
  3. Wu, L et al. The elusive NMN transporter is found. Nat Metab 2019: 1; 8-9  View Full Paper
  4. Rajman L et al. Therapeutic potential of NAD-Boosting molecules: The in vivo evidence. Cell Metab. 2018 Mar 6;27(3):529-547. View Abstract
  5. Li W et al. NAD+ Content and Its Role in Mitochondria. Mitochondrial Regulation. 2014: 39–48 View Abstract
  6. Lee CF et al. Targeting NAD+ metabolism as interventions for mitochondrial disease. Sci Rep. 2019 Feb 28;9(1):3073. View Abstract
  7. Schultz MB et al. Why NAD+ Declines during Aging: It’s Destroyed. Cell Metab. 2016 June 14; 23(6): 965–966 View Full Paper
  8. Davila, A et al. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. Elife. 2018 Jun 12;7 View Full Paper
  9. Imai S. The NAD World 2.0: the importance of the inter-tissue communication mediated by NAMPT/NAD+/SIRT1 in mammalian aging and longevity control. NPJ Syst Biol Appl. 2016 Aug 18;2:16018 View Full Paper
  10. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue PLoS One. 2012;7(7):e42357 View Abstract
  11. Zhu XH et al. In vivo NAD assay revels the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. 2015; 112:2876–2881 View Full Paper
  12. Hershberger KA et al. Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol. 2017 Apr;13(4):213-225. View Full Paper
  13. Gross CJ et al. Digestion and absorption of NAD by the small intestine of the rat J Nutr. 1983 Feb;113(2):412-20. View Abstract
  14. Poljsak B. NAMPT-Mediated NAD biosynthesis as the internal timing mechanism: in NAD+ World, time Is running in its own way. Rejuvenation Res. 2018 Jun;21(3):210-224 View Abstract
  15. Tsubota, K. The first human clinical study for NMN has started in Japan. NPJ Aging Mech. Dis. 2016, 2, 16021 View Abstract
  16. Strait, JE. Scientists identify new fuel-delivery route for cells. Washington University School of Medicine. Available at: https://medicine.wustl.edu/news/scientists-identify-new-fuel-delivery-route-for-cells/ Accessed: 9-14-2019
  17. Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016: 24, 795–806. View Full Paper
  18. Anti-Aging compound in human clinical trial: will boosting NMN slow aging? Available at: https://hecmedia.org/posts/anti-aging-compound-in-human-clinical-trial-will-boosting-nmn-slow-aging-6/ Accessed 9-1-2019
  19. Guan Y et al. Nicotinamide Mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J Am Soc Nephrol. 2017 Aug;28(8):2337-2352. View Full Paper
  20. Martin As et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model.JCI Insight. 2017 Jul 20;2(14). View Full Paper
  21. Johnson S et al. NAD + biosynthesis, aging, and disease. F1000Res. 2018 Feb 1;7:132 View Full Paper
  22. Mills KF et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016; 24:795–806 View Full Paper
  23. Das A et al. Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging. Cell. 2018 Mar 22;173(1):74-89.e20 View Abstract
  24. Kathirvel E et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1068-77  View Full Paper
  25. Schmeisser K et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol. 2013;9(11):693–700. View Full Paper
  26. Bonkowski MS et al. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016 November ; 17(11): 679–690 View Full Paper
  27. Kane AE et al. Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular disease. Circ Res. 2018 Sep 14;123(7):868-885. View Full Paper
  28. Sun WP et al. Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clin Nutr, 2017. 36(4): p. 1136-1142 View Abstract
  29. Van der Meel R et al. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014 Dec 10;195:72-85 View Abstract
  30. Yoshida M. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 2019 Aug 6;30(2):329-342.e5 View Abstract
  31. Yoshino J et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018 Mar 6;27(3):513-528 View Full Paper
  32. Gaddipati R et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010;9(3):266–70. View Abstract
  33. Revollo JR et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363–75 View Full Paper
  34. Caton PW et al. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated
  35. impairment of mouse islet function. Diabetologia. 2011;54(12):3083–92. View Abstract
  36. De Picciotto NE et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 2016, 15, 522–530. View Full Paper
  37. Yoshino J et al. Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36 View Full Paper
  38. Uddin GM et al. Head to Head Comparison of Short-Term Treatment with the NAD(+) Precursor Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese Female Mice. Front. Pharmacol. 2016, 7, 258 View Full Paper
  39. Wei CC et al. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci. Rep. 2017, 7, 717 View Full Paper
  40. Wang X et al. Nicotinamide mononucleotide protects against –amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 2016, 1643, 1–9. View abstract
  41. Yao Z et al. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 2017, 647, 133–140. View Abstract
  42. Hou Y et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl. Acad. Sci. USA 2018, 115, E1876–E1885 View Abstract
  43. Wei CC et al. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia. Br J Pharmacol. 2017 Nov;174(21):3823-3836 View Full Paper
  44. Gomes AP et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 2013; 155, 1624–1638.View Full Paper
  45. Stromsdorfer KL et al. NAMPT-Mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 2016 Aug 16;16(7):1851-60. View Abstract
  46. Camacho-Pereira J et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23:1127–1139 View Full Paper
  47. Lin JB et al. NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice. Cell Rep. 2016; 17:69–85 View Full Paper
  48. Sheedfar F et al. Liver diseases and aging: friends or foes? Aging Cell. 2013 Dec;12(6):950-4 View Abstract
  49. Hamaguchi M. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women.
  50. World J Gastroenterol. 2012 Jan 21;18(3):237-43 View Full Paper
  51. Day CR et al. Betaine chemistry, roles, and potential use in liver disease. Biochim Biophys Acta. 2016 Jun;1860(6):1098-106 View Abstract
  52. Zhao G et al. Betaine in inflammation: mechanistic aspects and applications.  Front Immunol. 2018 May 24;9:1070. View Full Paper
  53. Ueland PM et al. Betaine: a key modulator of one-carbon metabolism and homocysteine status.
  54. Clin Chem Lab Med. 2005;43(10):1069-75. View Abstract
  55. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004 Sep;80(3):539-49. View Abstract
0
Your Cart